What is the 13F Pro Quality Score for ANAB?

13F Pro ranks ANAPTYSBIO, INC (ANAB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANAB's current score at https://13fpro.ai/research/ANAB (free sign-up required for the full ranking).

Which hedge funds own the most ANAB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ANAB include EcoR1 Capital,, BlackRock,, TANG CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ANAB as soon as new 13F filings post.

Where does 13F Pro source ANAB data?

All ANAPTYSBIO, INC fundamentals and ownership data come directly from SEC EDGAR. ANAPTYSBIO, INC files with the SEC under CIK 1370053. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANAB in?

ANAPTYSBIO, INC (ANAB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANAB research updated on 13F Pro?

ANAB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ANAPTYSBIO, INC(ANAB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1370053 ANAB stock profile & AI dashboard →

13F Pro Quality Score

29.4/100

Rank #2,408 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

98.3/100

Profitability

8.8/100

Balance Sheet

7.0/100

Earnings Quality

30.0/100

Free Cash Flow

7.8/100

Institutional Flow

8.8/100

Revenue Scale

21.2/100

Dilution Risk

12.2/100

ANAB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ANAPTYSBIO, INC (ANAB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANAB at 29.4/100 on a 32-signal composite quality model, placing it at rank #2,408 of 2,879 stocks — the bottom half of the AI-ranked universe. ANAB scores in the top quartile across revenue growth (98.3). Areas of concern include balance sheet strength (7.0) and free cash flow (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ANAPTYSBIO, INC reports quarterly revenue of $25.6M, net income of $-52.9M, free cash flow of $-25.9M. Top institutional holders of ANAB by reported 13-F value include EcoR1 Capital,, BlackRock,, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. ANAB trades on the Nasdaq exchange and files with the SEC under CIK 1370053. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANAPTYSBIO, INC directly from SEC EDGAR. ANAPTYSBIO, INC's 13F Pro composite quality score has ranged between 8 and 84 since 2021, currently 29.4 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ANAPTYSBIO, INC

Quirks, history, and lore behind ANAB — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
A small-cap biotech with minimal product revenue — it runs on a mix of collaboration deals and milestone payments while spending heavily on R&D, as clinical-stage companies do.
3
The History
Founded in the early 2010s, the company was built around a proprietary platform for discovering fully human monoclonal antibodies — the kind of science that takes years to pay off, if ever.
4
The Secret
Its pipeline targets inflammatory and immuno-oncology diseases, including conditions driven by overactive immune cells — think itching, rashes, and the body attacking itself.
5
The Lore
The company inked a significant collaboration with GSK around its antibody assets, a partnership that brought in substantial non-dilutive cash — a rare win for a small biotech.
6
The Giveaway
Its name is a mashup of antibody science and Greek roots — and its lead programs chase severe atopic dermatitis and prurigo nodularis, itchy diseases that big pharma largely ignored.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$25.6M

Net Income

Q1 2026

$-52.9M

Free Cash Flow

Q1 2026

$-25.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+66.8% YoY

$17.2MFY 2023

FY20 $75.0MFY21 $63.2MFY22 $10.3MFY23 $17.2M

Net Income

-27.1% YoY

$-163.6MFY 2023

FY20 $-19.9MFY21 $-57.8MFY22 $-128.7MFY23 $-163.6M

Operating Income

-42.8% YoY

$-164.4MFY 2023

FY20 $-23.9MFY21 $-56.8MFY22 $-115.2MFY23 $-164.4M

EPS (Diluted)

-33.0% YoY

$-6.08FY 2023

FY20 $-0.73FY21 $-2.11FY22 $-4.57FY23 $-6.08

Total Assets

-25.9% YoY

$452.4MFY 2023

FY20 $416.6MFY21 $643.1MFY22 $610.4MFY23 $452.4M

Op. Cash Flow

-64.1% YoY

$-120.8MFY 2023

FY20 $-14.2MFY21 $-45.9MFY22 $-73.6MFY23 $-120.8M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$17.2M +66.8%	$10.3M -83.7%	$63.2M -15.8%	$75.0M +1400.0%	$5.0M -50.0%	$10.0M
Net Income	$-163.6M -27.1%	$-128.7M -122.7%	$-57.8M -190.0%	$-19.9M +67.7%	$-61.7M -105.0%	$-30.1M
Operating Income	$-164.4M -42.8%	$-115.2M -102.7%	$-56.8M -137.9%	$-23.9M +64.2%	$-66.7M -131.8%	$-28.8M
EPS (Diluted)	$-6.08 -33.0%	$-4.57 -116.6%	$-2.11 -189.0%	$-0.73 +70.8%	$-2.50 -64.5%	$-1.52
Total Assets	$452.4M -25.9%	$610.4M -5.1%	$643.1M +54.4%	$416.6M -18.2%	$509.0M +54.5%	$329.4M
Operating Cash Flow	$-120.8M -64.1%	$-73.6M -60.3%	$-45.9M -224.4%	$-14.2M +70.8%	$-48.5M -149.5%	$-19.4M

Get alerted when ANAB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ANAPTYSBIO, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANAB

EcoR1 Capital, LLC
$437.0M7,880,094 sh
BlackRock, Inc.
$93.2M1,681,380 sh
TANG CAPITAL MANAGEMENT LLC
$73.8M1,330,879 sh
MORGAN STANLEY
$55.1M993,905 sh
STATE STREET CORP
$55.0M992,445 sh
Affinity Asset Advisors, LLC
$52.1M940,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$47.3M853,151 sh
Palo Alto Investors LP
$35.4M638,161 sh
683 Capital Management, LLC
$34.7M625,000 sh
D. E. Shaw & Co., Inc.
$32.1M579,296 sh

Fund	Value	Shares
EcoR1 Capital, LLC	$437.0M	7,880,094
BlackRock, Inc.	$93.2M	1,681,380
TANG CAPITAL MANAGEMENT LLC	$73.8M	1,330,879
MORGAN STANLEY	$55.1M	993,905
STATE STREET CORP	$55.0M	992,445
Affinity Asset Advisors, LLC	$52.1M	940,000
VANGUARD CAPITAL MANAGEMENT LLC	$47.3M	853,151
Palo Alto Investors LP	$35.4M	638,161
683 Capital Management, LLC	$34.7M	625,000
D. E. Shaw & Co., Inc.	$32.1M	579,296

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANAB on your watchlist

Track score changes the day ANAPTYSBIO, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANAB a good stock to buy?

13F Pro's AI-powered analysis of ANAPTYSBIO, INC (ANAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANAB are available on the ANAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ANAB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANAPTYSBIO, INC's investment landscape.